Symbiotec IPO: Promoters See 260% Gain, Jhunjhunwala's Bet Up 45.6x!
Symbiotec IPO: Promoters See 260% Gain, Jhunjhunwala's Bet Up 45.6x!
Symbiotec Pharmalab's upcoming IPO is set to deliver massive returns! Promoters could see 260% gain, while Rakesh Jhunjhunwala's long-term investment skyrockets 45.6 times. Get the full scoop on this blockbuster market e
The much-anticipated Initial Public Offering (IPO) of Symbiotec Pharmalab is generating significant buzz, not just for its market debut but for the staggering returns it promises to its early investors and promoters. At the upper end of the IPO price band of Rs 988 per share, promoters are looking at an impressive gain of approximately 260% in just eight months since the company filed its draft papers last December. This strong performance highlights a remarkable growth trajectory ahead of its public offering.
The Rs 1,757 crore IPO, which will open for bidding from August 24 to August 26, comprises a fresh share sale of Rs 150 crore and a substantial offer-for-sale (OFS) of up to Rs 1,607 crore. Among the key beneficiaries is promoter entity Satwani Holdings, which is offloading shares worth Rs 144 crore. With a weighted average cost of acquisition (WACA) of just Rs 49.43 apiece, Satwani Holdings is poised to make a phenomenal 1,900 per cent profit on its sold shares. Other participating entities in the OFS, India Business Excellence Fund-III and Rosewood Investments, are also set to achieve handsome returns of around 570% based on their WACA of Rs 147.21 per share.
Adding to the excitement is the incredible journey of ace investor Rakesh Jhunjhunwala's investment in Symbiotec. Having initially invested Rs 7.5 crore in August 2007 for 5,22,000 equity shares at Rs 143.68 apiece, he further increased his stake with an additional investment of Rs 41.76 lakh through a rights issue in July 2009. His total investment amounted to nearly Rs 7.92 crore for 7,30,800 shares. Following a stock split in the first half of 2025, his adjusted cost of acquisition stands at Rs 21.67 per share. At the IPO's issue price, the value of Jhunjhunwala's holding is projected to be around Rs 361 crore, representing an astounding 45.6 times surge from his original investment and a notional return of up to 4,460 per cent. This exemplifies the potential for long-term strategic investments.
The IPO is being managed by prominent book-running lead managers including JM Financial Ltd, Avendus Capital, Motilal Oswal Investment Advisors, and Nomura Financial Advisory, with MUFG Intime India serving as the registrar. The shares of Symbiotec Pharmalab are slated for listing on both the BSE and NSE, promising a new chapter for the pharmaceutical company and its investors.
